Page last updated: 2024-10-19

melatonin and Scleroderma, Systemic

melatonin has been researched along with Scleroderma, Systemic in 1 studies

Scleroderma, Systemic: A chronic multi-system disorder of CONNECTIVE TISSUE. It is characterized by SCLEROSIS in the SKIN, the LUNGS, the HEART, the GASTROINTESTINAL TRACT, the KIDNEYS, and the MUSCULOSKELETAL SYSTEM. Other important features include diseased small BLOOD VESSELS and AUTOANTIBODIES. The disorder is named for its most prominent feature (hard skin), and classified into subsets by the extent of skin thickening: LIMITED SCLERODERMA and DIFFUSE SCLERODERMA.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Simonini, G1
Pignone, A1
Generini, S1
Falcini, F1
Cerinic, MM1
Gabriele, S1
Alberto, P1
Sergio, G1
Fernanda, F1
Marco, MC1

Reviews

1 review available for melatonin and Scleroderma, Systemic

ArticleYear
Emerging potentials for an antioxidant therapy as a new approach to the treatment of systemic sclerosis.
    Toxicology, 2000, Nov-30, Volume: 155, Issue:1-3

    Topics: Antioxidants; Ascorbic Acid; beta Carotene; Endothelium, Vascular; Humans; In Vitro Techniques; Mela

2000